Summary
Amgen Inc. (AMGN) filed an 8-K on February 2, 2021, to furnish a press release detailing its fourth quarter and full-year 2020 financial results. The report highlights Amgen's use of non-GAAP financial measures to provide a clearer view of its operational performance, excluding items such as acquisition-related expenses, restructuring costs, and certain investment gains/losses. These adjustments aim to facilitate better comparisons of ongoing business performance across periods. Investors should note that the company is refining its non-GAAP presentation starting January 1, 2021, by excluding gains and losses from equity securities investments that are recorded in interest and other income. This change is intended to improve the comparability of financial performance by reducing the impact of investment volatility on core business results, while continuing to exclude results from strategic equity method investments like BeiGene. The press release itself is furnished as an exhibit and not deemed 'filed' for liability purposes.
Key Highlights
- 1Amgen reported its fourth quarter and full-year 2020 financial results on February 2, 2021.
- 2The company utilizes non-GAAP financial measures (e.g., non-GAAP EPS, non-GAAP operating income) for enhanced investor analysis.
- 3Key exclusions from non-GAAP measures include acquisition-related expenses (e.g., amortization of intangibles, impairment of in-process R&D).
- 4Restructuring costs, related to transformation and process improvement efforts, are also excluded from non-GAAP calculations.
- 5Certain investment-related gains/losses and legal settlement items are adjusted for in non-GAAP reporting, deemed outside ordinary business.
- 6Amgen is enhancing its non-GAAP presentation starting January 1, 2021, by excluding gains/losses on equity securities from interest and other income.
- 7Free Cash Flow (FCF) is also presented as a measure of liquidity, calculated as operating cash flow less capital expenditures.